Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
1680
¥ million (approximate total amount)Wording
Conditional
How definitive the wording is.This transaction
Acquisition of shares and conversion into a subsidiaryCounterpartySEKAISHA Co., Ltd., としすみ Co., Ltd., Fujii Tatsuki (藤井 達樹), Other transferors (1 company and 2 individuals; names not stated in the document)
Disclosing companyRelo Group,Inc.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
Management consulting services for medical institutions
Location SingaporeShare capital 2,614,370 SGDDate of incorporation 11 April 2022
Net SalesSGD 10,965,919 (fiscal year ended March 2026)
Operating profitSGD 1,458,813 (fiscal year ended March 2026)
Net income for the current fiscal yearSGD 1,154,139 (fiscal year ended March 2026)
Net assetsSGD 3,943,746 (fiscal year ended March 2026)
Consideration and expenses
Acquisition priceATIV Medical ordinary shares: ¥1,620 million
Expenses other than the acquisition price¥60 million in advisory fees and other costs (estimated)
Impact on Business Performance
Currently under review. However, the Company believes the transaction will contribute to improved performance.
Procedures and assumptions
Management structure after acquisitionThe policy is to combine the strengths of the two companies and improve the quality of services for overseas assignees. The trade name, representative and treatment of employees are not disclosed.
| Item | Details |
|---|---|
| Transaction name | Acquisition of shares and conversion into a subsidiary |
| Counterparty name | SEKAISHA Co., Ltd., としすみ Co., Ltd., Fujii Tatsuki (藤井 達樹), Other transferors (1 company and 2 individuals; names not stated in the document) |
| Name of the Subject Company | ATIV Medical Pte. Ltd. |
| Business Description of the Subject Company | Management consulting services for medical institutions |
| Location of the Subject Company | Singapore |
| Capital Stock of the Subject Company | 2,614,370 SGD |
| Date of Establishment of the Subject Company | 11 April 2022 |
| Net Sales of the Subject Company | SGD 10,965,919 (fiscal year ended March 2026) |
| Operating Profit of the Subject Company | SGD 1,458,813 (fiscal year ended March 2026) |
| Net Income of the Subject Company | SGD 1,154,139 (fiscal year ended March 2026) |
| Net Assets of the Subject Company | SGD 3,943,746 (fiscal year ended March 2026) |
| Acquisition price | ATIV Medical ordinary shares: ¥1,620 million |
| Expenses other than the acquisition price | ¥60 million in advisory fees and other costs (estimated) |
| Number of shares acquired | 242,910,000 shares (number of voting rights: 242,910,000) |
| Voting rights ownership percentage | Before 0% → after 90.0% |
| Impact on Business Performance | Currently under review. However, the Company believes the transaction will contribute to improved performance. |
| Contract Date | 20 October 2026 |
| Execution Date / Effective Date | 30 October 2026 (scheduled) |
| Management structure after acquisition | The policy is to combine the strengths of the two companies and improve the quality of services for overseas assignees. The trade name, representative and treatment of employees are not disclosed. |
Items this document does not state (13)
Type of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To connect the overseas assignment support business with ATIV Medical's medical services and create a service network covering the period from before an overseas assignment through life in the destination country, thereby generating customer-referral synergies and improving corporate value and the quality of services for overseas assignees.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.